Proteomics in Morbid Obesity After Bariatric Surgery (PROTOBESE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01151917|
Recruitment Status : Completed
First Posted : June 29, 2010
Last Update Posted : January 30, 2014
|Condition or disease|
|Insulin Resistance Proteomics Morbid Obesity|
Show Detailed Description
|Study Type :||Observational|
|Actual Enrollment :||20 participants|
|Official Title:||Identification of a Novel Factor(s) of Importance to Insulin Resistance -Repeated Blood Sampling Before and After Biliopancreatic Diversion|
|Study Start Date :||June 2009|
|Actual Primary Completion Date :||January 2011|
|Actual Study Completion Date :||July 2012|
Each subject is own control
- Proteomics [ Time Frame: 2 years ]used to identify plasma proteins or peptides that may be involved in the remarkably fast and explicit restoration of insulin sensitivity seen in morbidly obese patients with insulin resistance shortly after gastric bypass surgery by BPD.
- Insulin sensitivity and secretion and incretins [ Time Frame: 2 years ]Selection of recognized markers for metabolic control. Insulin secretion is measured by C-peptide deconvolution and insulin sensitivity by minimal modelling of glucose-insulin after a meal. Increatins will be measured too.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01151917
|Day Hospital of Metabolic Diseases, Catholic University|
|Rome, Italy, 00168|
|Principal Investigator:||Geltrude Mingrone, Professor||Catholic University of Rome|